[Different chemotherapy protocols for intermediate and high grade malignant non-Hodgkin's lymphoma].

OBJECTIVE: To assess the optinums chemotherapeutic protocols for higher CR rate in the treatment of intermediate and high grade malignant non Hodgin's lyphoma(NHL).

METHODS: Seventy-four patients with pathological intermediate and high grade malignant NHL were tried randomly with revised ProMACE-CytaBOM(treatment group) and CHOP(control group).

RESULTS: The CR rate was 56.8% in the treatment group and 35.0% in the control group (P > 0.05). In patients with high grade maliganat NHL, the CR rate of ProMACE-CytaBOM was 60.0% as compared with 32.0% of the CHOP (P < 0.05). Patients in both group suffered from similar side effects with tolerable bone marrow supression and gastric irritation.

CONCLUSION: ProMACE-CytaBOM is a safe regimen with relative high CR rate for high grade malignant NHL, but further research is indicated for remote results.